The drugstore chain owns CVS Caremark, one of the largest pharmacy benefit managers in the nation. PBMs are responsible for contracting with pharmacies, negotiating rebates or discounts and processing prescription drug claims for insurers. Critics have long blamed these middlemen for the rising drug prices and high out-of-pocket costs for patients because these rebates are often confidential.
“Drug manufacturers want you to believe that increasing drug prices are a result of them [being] happy to pay rebates and that PBMs are retaining these rebates,” Mr. Merlo told the WSJ. “And this is simply not true.”
During a conference call Aug. 8 discussing the company’s second-quarter earnings, Mr. Merlo said CVS expects 3 percent, or $300 million, of its 2018 earnings to come from rebates.
In addition, Mr. Merlo disclosed that his company has generate tens of billions of dollars in rebates and 98 percent of those funds are passed to its clients.
CVS’s pushback is the latest in the debate over who is responsible for increasing drug prices in the U.S.
More articles on pharmacy:
Teva’s revenue drops 18% in Q2
Express Scripts to drop coverage of 48 drugs next year
Trump to make drug price announcement next week
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
